Literature DB >> 10917466

Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction.

G Fiorini1, S Crespi, M Rinaldi, E Oberti, R Vigorelli, G Palmieri.   

Abstract

Many studies have demonstrated that, in asthma, serum levels of eosinophil cationic protein (ECP) are related to the activity and severity of the disease and can be used to evaluate the response to steroid treatment. During exacerbations of chronic bronchitis, airway inflammation shows some features of asthmatic inflammatory processes, with recruitment of eosinophils and recovery of significant amounts of ECP in bronchial lavage fluid (BAL). Involvement of neutrophils, with high levels of myeloperoxidase (MPO), is, on the contrary, typical of this latter disease, and not shared with asthma. In spite of the information collected with BAL and bronchial biopsy studies, few data still exist on serum levels of these proteins in chronic bronchitis. The objective of this study was to assess if serum levels of ECP and MPO are specifically increased in exacerbations of chronic bronchitis, as compared to other non-asthmatic acute respiratory disturbances. Serum ECP, MPO and immunoglobulin E (IgE) levels were measured in 17 non-atopic patients with exacerbation of chronic bronchitis with airway obstruction (COPD) and in 11 control subjects seeking emergency medical treatment for unrelated acute respiratory problems. Spirometry was performed in patients able to give the necessary collaboration. All the subjects of this study were recruited from the emergency department. Both ECP and MPO were significantly increased in serum from patients with exacerbated COPD (22.2 +/- 4.1 vs 9.5 +/- 1.4 mcg/L and 853 +/- 168 vs 375 +/- 41 mcg/L) and a strong correlation existed between these two variables (r = 0.782). A further control group was made of 11 patients with stable COPD. These subjects had levels of both ECP (13.1 +/- 2.7 mcg/L) and MPO (469 +/- 71) significantly lower than patients with exacerbated disease and higher than those without COPD. We conclude that serum ECP and MPO are increased during the exacerbations of COPD. These observations can give a basis for further studies aimed to evaluate the utility of these two proteins as markers of activity and severity of COPD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10917466     DOI: 10.1016/S0753-3322(00)80071-2

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  14 in total

Review 1.  The Beneficial Effects of Antioxidants in Health And Diseases.

Authors:  Sabina Janciauskiene
Journal:  Chronic Obstr Pulm Dis       Date:  2020-07

Review 2.  COPD exacerbations . 2: aetiology.

Authors:  E Sapey; R A Stockley
Journal:  Thorax       Date:  2006-03       Impact factor: 9.139

3.  Eosinophilic biomarkers for detection of acute exacerbation of chronic obstructive pulmonary disease with or without pulmonary embolism.

Authors:  Qiong-Fang Yang; Ting-Ting Lu; Cai-Min Shu; Lan-Fang Feng; Hao-Teng Chang; Qiao-Ying Ji
Journal:  Exp Ther Med       Date:  2017-08-02       Impact factor: 2.447

Review 4.  The Role of HMGB1, a Nuclear Damage-Associated Molecular Pattern Molecule, in the Pathogenesis of Lung Diseases.

Authors:  Mao Wang; Alex Gauthier; LeeAnne Daley; Katelyn Dial; Jiaqi Wu; Joanna Woo; Mosi Lin; Charles Ashby; Lin L Mantell
Journal:  Antioxid Redox Signal       Date:  2019-07-11       Impact factor: 8.401

5.  Clinical value of IL-13 and ECP in the serum and sputum of eosinophilic AECOPD patients.

Authors:  Ting Li; Li Gao; Hong-Xia Ma; Yang-Yang Wei; Yue-Hua Liu; Ke-Ru Qin; Wen-Tao Wang; Hai-Long Wang; Min Pang
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-03

6.  Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations.

Authors:  M A Dentener; E C Creutzberg; A M Schols; A Mantovani; C van't Veer; W A Buurman; E F Wouters
Journal:  Thorax       Date:  2001-09       Impact factor: 9.139

Review 7.  Chronic obstructive pulmonary disease. 5: systemic effects of COPD.

Authors:  E F M Wouters
Journal:  Thorax       Date:  2002-12       Impact factor: 9.139

Review 8.  Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of chronic obstructive pulmonary disease.

Authors:  A J White; S Gompertz; R A Stockley
Journal:  Thorax       Date:  2003-01       Impact factor: 9.139

9.  COPD association and repeatability of blood biomarkers in the ECLIPSE cohort.

Authors:  Jennifer A Dickens; Bruce E Miller; Lisa D Edwards; Edwin K Silverman; David A Lomas; Ruth Tal-Singer
Journal:  Respir Res       Date:  2011-11-04

Review 10.  Airways inflammation and treatment during acute exacerbations of COPD.

Authors:  Erik Bathoorn; Huib Kerstjens; Dirkje Postma; Wim Timens; William MacNee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.